Lancashire and South Cumbria
Formulary
Formulary
11 Eye
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
11-06 Beta-blockers
CSM advice: Beta-blockers, even those with cardioselectivity should be avoided in patients with asthma or a history of COPD unless no other alternative treatment is available - see BNF
CSM advice: Beta-blockers, even those with cardioselectivity should be avoided in patients with asthma or a history of COPD unless no other alternative treatment is available - see BNF
| Timolol |
|
First Choice
|
eye drops 0.25%, 0.5% |
|
| Betaxolol Betoptic® |
|
Second Choice
|
Eye drops 0.25%, 0.5% *under review* Not listed on East Lancashire formulary |
|
|
| Levobunolol Betagan® |
|
Formulary
|
Unit dose - preservative free eye drops levobunolol 0.5%/polyvinyl alcohol 1.4% *under review* Not listed on East Lancashire formulary |
|
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG81: Glaucoma: diagnosis and management